How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,918 results for

macrolides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Draft Genome Sequence of a Shewanella halifaxensis Strain Isolated from the Intestine of Marine Red Seabream (Pagrus major), Which Includes an Integrative Conjugative Element with Macrolide Resistance Genes (Full text)

Draft Genome Sequence of a Shewanella halifaxensis Strain Isolated from the Intestine of Marine Red Seabream (Pagrus major), Which Includes an Integrative Conjugative Element with Macrolide Resistance Genes Shewanella halifaxensis strain 6JANF4-E-4 was isolated from the intestine of a red seabream (Pagrus major). Here, we report the draft genome sequence of this bacterium, which includes an integrative conjugative element of the SXT/R391 family, where the macrolide resistance determinants mef(C

2018 Genome Announcements PubMed abstract

142. Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities (Full text)

Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities Some studies have found that antimicrobials, especially macrolides, increase the risk of cardiovascular death. We investigated potential cardiac-related events associated with antimicrobial use in a population of patients with acute myocardial infarction.For 185 010 Medicare beneficiaries, we recorded prescriptions for azithromycin (...) myocardial infarction, number of visits, and the influenza rate. In unadjusted analyses, macrolides and fluoroquinolones were associated with a risk of cardiac events. However, the risk associated with macrolide use was substantially attenuated after adjustment for a wide range of variables, and the risk associated with fluoroquinolones was no longer statistically significant. For example, for azithromycin, the odds ratio for any cardiac event or death was 1.35 (95% confidence interval, 1.27-1.44; P

2018 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease PubMed abstract

143. Development of macrolide resistance in Bordetella bronchiseptica is associated with the loss of virulence. (Full text)

Development of macrolide resistance in Bordetella bronchiseptica is associated with the loss of virulence. Why resistance to specific antibiotics emerges and spreads rapidly in some bacteria confronting these drugs but not others remains a mystery. Resistance to erythromycin in the respiratory pathogens Staphylococcus aureus and Streptococcus pneumoniae emerged rapidly and increased problematically. However, resistance is uncommon amongst the classic Bordetella species despite infections being (...) treated with this macrolide for decades.We examined whether the apparent progenitor of the classic Bordetella spp., Bordetella bronchiseptica, is able to rapidly generate de novo resistance to antibiotics and, if so, why such resistance might not persist and propagate.Independent strains of B. bronchiseptica resistant to erythromycin were generated in vitro by successively passaging them in increasing subinhibitory concentrations of this macrolide. Resistant mutants obtained were evaluated

2018 Journal of Antimicrobial Chemotherapy PubMed abstract

144. Azithromycin susceptibility in Neisseria gonorrhoeae and seasonal macrolide use. (Full text)

Azithromycin susceptibility in Neisseria gonorrhoeae and seasonal macrolide use. Rising azithromycin nonsusceptibility among Neisseria gonorrhoeae isolates threatens current treatment recommendations, but the cause of this rise is not well understood. We performed an ecological study of seasonal patterns in macrolide use and azithromycin resistance in N. gonorrhoeae, finding that population-wide macrolide use is associated with increased azithromycin nonsusceptibility. These results, indicative

2018 Journal of Infectious Diseases PubMed abstract

145. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. (Full text)

Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objective of this study was to define the clinical outcomes of patients with CAP and bacteremia treated with and without a macrolide.Secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with CAP. Patients with a positive blood culture were categorized based (...) on the presence or absence of a macrolide in their initial antimicrobial regimen, and severity of their CAP. Outcomes included in-hospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability.Among 549 patients with CAP and bacteremia, 247 (45%) were treated with a macrolide and 302 (55%) were not. The primary pathogen was Streptococcus pneumoniae (74%). Poisson regression with robust error variance models were used to compare the adjusted effects of each study group

2018 Respiratory medicine PubMed abstract

146. Emergence of resistance to macrolides and rifampicin in clinical isolates of <i>Rhodococcus equi</i> from foals in central Kentucky, USA: 1995 to 2017. (Full text)

Emergence of resistance to macrolides and rifampicin in clinical isolates of Rhodococcus equi from foals in central Kentucky, USA: 1995 to 2017. The objective of this study was to determine the prevalence of Rhodococcus equi strains resistant to macrolides and rifampin over time in clinical samples from foals submitted to diagnostic laboratories in central Kentucky. We performed a retrospective observational study of all clinical samples from foals that were submitted to veterinary (...) , or musculoskeletal infections. The considerable increase in the prevalence of isolates of R. equi resistant to macrolides and rifampin since 2007 is of concern for both human and animal health.Copyright © 2018 American Society for Microbiology.

2018 Antimicrobial Agents and Chemotherapy PubMed abstract

147. Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department. (Abstract)

Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department. Emergency physicians are under pressure to prescribe an antibiotic early in the treatment course of a patient with community-acquired pneumonia (CAP). Macrolides are recommended first-line empirical therapy for the outpatient treatment of CAP in patients without associated comorbidities; however, resistance rates to macrolides in the United States are on the rise.This review considers macrolide (...) use for CAP in the emergency department by reviewing the microbiologic environment in the United States and whether macrolides can overcome in vitro resistance during actual clinical use. Alternatives to macrolides for CAP are briefly discussed.Resistance to macrolides is now above 25% in all regions of the United States, and resistance to other antibiotics is also on the rise. The failure of outpatient macrolide treatment for CAP because of resistance rates increases the burden of the disease

2018 Journal of Emergency Medicine

148. Treatment of Macrolide-resistant Mycoplasma Pneumoniae

Treatment of Macrolide-resistant Mycoplasma Pneumoniae Treatment of Macrolide-resistant Mycoplasma Pneumoniae - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Macrolide-resistant Mycoplasma (...) . Proportionally, M. pneumoniae has become the most important pathogen for childhood pneumonia after the widespread use of Streptococcus pneumoniae vaccines. M. pneumoniae is routinely treated with antibiotics, and the macrolides antibiotics are the drug of choice for M. pneumonia infection. However, macrolide-resistance rates have increased to 20 and 100% in Asia. In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. The evolution and spreading

2018 Clinical Trials

149. Cohort study: Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis (Full text)

Cohort study: Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis Article

2014 Evidence-Based Medicine PubMed abstract

150. In Vitro Activity of Lefamulin and Other Antimicrobial Agents Against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. (Full text)

In Vitro Activity of Lefamulin and Other Antimicrobial Agents Against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active (...) against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.Copyright © 2017 American Society for Microbiology.

2016 Antimicrobial Agents and Chemotherapy PubMed abstract

151. A systematic review and meta-analysis of surgical site infection post- caesarean section following prophylactic adjunctive macrolides.

A systematic review and meta-analysis of surgical site infection post- caesarean section following prophylactic adjunctive macrolides. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

152. Comparing the clinical outcomes of quinolones versus macrolides in the treatment of legionella pneumonia: a systematic review and meta-analysis

Comparing the clinical outcomes of quinolones versus macrolides in the treatment of legionella pneumonia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

153. Clinical characteristics and treatment outcome of patients with macrolide-resistant mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis

Clinical characteristics and treatment outcome of patients with macrolide-resistant mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

154. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial. (Abstract)

Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial. The mechanism by which low-dose macrolide therapy reduces exacerbations in non-cystic fibrosis bronchiectasis is not known. Pseudomonas aeruginosa quorum sensing controls the expression of a range of pathogenicity traits and is inhibited by macrolide in vitro. Quorum sensing inhibition renders P. aeruginosa less

2017 Annals of the American Thoracic Society Controlled trial quality: uncertain

155. The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. (Full text)

The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. There is currently conflicting level 1 evidence in the use of long-term antibiotics for chronic rhinosinusitis without nasal polyps. The primary aim of this feasibility study was to optimise future randomised trial design by assessing recruitment and retention of patients alongside providing preliminary data on symptomatic control.Prospective, multicentre feasibility (cohort) study with all patients (...) receiving macrolide therapy for 12 weeks and a further subsequent 12-week follow-up. Participants received a 12-week course of clarithromycin 250 mg alongside twice daily topical mometasone and nasal douching. Primary outcomes focused on recruitment, retention and compliance. Clinical and quality-of-life outcomes measures were also recorded.Patients were prospectively recruited from six UK outpatient clinics.Adult patients with chronic rhinosinusitis without nasal polyps and no prior endoscopic sinus

2017 Clinical Otolaryngology PubMed abstract

156. Long-term low-dose macrolides for chronic rhinosinusitis in adults - a systematic review of the literature. (Abstract)

Long-term low-dose macrolides for chronic rhinosinusitis in adults - a systematic review of the literature. Chronic rhinosinusitis is a very common inflammatory disease that impairs quality of life and is associated with high healthcare spending. Chronic rhinosinusitis treatment commonly involves the use of intranasal corticosteroids, oral antibiotics, and surgery. Macrolides have been identified as a potential treatment option for chronic rhinosinusitis due to their immunomodulatory effects (...) ; however, the evidence supporting their use is still conflicting.The purpose of this systematic review was to evaluate new evidence along with previously reported studies of the use of macrolides in the treatment of chronic rhinosinusitis.Medline, EMBASE, Cochrane CENTRAL, LILACS, clinicaltrials.gov, and the International Clinical Trials Registry Platform were all searched (until June 2015 Medline and EMBASE searches were updated January 2016). Randomised controlled trials comparing low-dose macrolide

2017 Clinical Otolaryngology

157. New macrolide-lincosamide-streptogramin B resistance gene <i>erm</i>(48) on the novel plasmid pJW2311 in <i>Staphylococcus xylosus</i>. (Full text)

New macrolide-lincosamide-streptogramin B resistance gene erm(48) on the novel plasmid pJW2311 in Staphylococcus xylosus. Whole-genome sequencing of Staphylococcus xylosus strain JW2311 from bovine mastitis milk identified the novel 49.3-kb macrolide-lincosamide-streptogramin B (MLSB) resistance plasmid pJW2311. It contained the macrolide resistance gene mph(C), the macrolide-streptogramin B resistance gene msr(A), and the new MLSB resistance gene erm(48) and could be transformed

2017 Antimicrobial Agents and Chemotherapy PubMed abstract

158. Macrolide resistance in Legionella pneumophila: the role of LpeAB efflux pump. (Full text)

Macrolide resistance in Legionella pneumophila: the role of LpeAB efflux pump. A previous study on 12 in vitro -selected azithromycin-resistant Legionella pneumophila lineages showed that ribosomal mutations were major macrolide resistance determinants. In addition to these mechanisms that have been well described in many species, mutations upstream of lpeAB operon, homologous to acrAB in Escherichia coli , were identified in two lineages. In this study, we investigated the role of LpeAB (...) and of these mutations in macrolide resistance of L. pneumophila .The role of LpeAB was studied by testing the antibiotic susceptibility of WT, deleted and complemented L. pneumophila Paris strains. Translational fusion experiments using GFP as a reporter were conducted to investigate the consequences of the mutations observed in the upstream sequence of lpeAB operon.We demonstrated the involvement of LpeAB in an efflux pump responsible for a macrolide-specific reduced susceptibility of L. pneumophila Paris strain

2017 Journal of Antimicrobial Chemotherapy PubMed abstract

160. Ribosomal mutations conferring macrolide resistance in Legionella pneumophila. (Full text)

Ribosomal mutations conferring macrolide resistance in Legionella pneumophila. Monitoring the emergence of antibiotic resistance is a recent issue in the treatment of Legionnaires' disease. Macrolides are recommended as first-line therapy, but resistance mechanisms have not been studied in Legionella species. Our aim was to determine the molecular basis of macrolide resistance in L. pneumophila Twelve independent lineages from a common susceptible L. pneumophila ancestral strain were propagated (...) under conditions of erythromycin or azithromycin pressure to produce high-level macrolide resistance. Whole-genome sequencing was performed on 12 selected clones, and we investigated mutations common to all lineages. We reconstructed the dynamics of mutation for each lineage and demonstrated their involvement in decreased susceptibility to macrolides. The resistant mutants were produced in a limited number of passages to obtain a 4,096-fold increase in erythromycin MICs. Mutations affected highly

2017 Antimicrobial Agents and Chemotherapy PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>